Two bills aim to close gaps and ensure equitable access by requiring private health insurance coverage of FDA-approved ...

Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial ...

Uppsala University announced today that BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) two founders, Lars Lannfelt and Pär Gellerfors, ...

Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...

Health is pioneering a new model of cognitive care, designed to increase access, improve outcomes, and support both patients and healthcare ...

Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of ...

Despite reporting positive Phase II results for its lead candidate last year, Vaccinex will soon no longer be a publicly ...

Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...

US-based Eli Lilly's Kisunla drug and Japanese company Eisai's Leqembi (below), two breakthrough drugs for the diagnosis and ...

It's hard to trust the disease statistics when cognitive tests often are not completed, write Robert Brownell and Dr. Yogesh ...

The UK’s National Institute for Health and Care Excellence (NICE) has issued further draft guidance reaffirming its decision ...

NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.